Atrial fibrillation (AF) is a significant cause of thromboembolism and stroke. Left atrial appendage (LAA) occlusion is associated with a decreased risk of stroke in patients with AF. Percutaneous implantation of the percutaneous LAA transcatheter occlusion (PLAATO) device has shown reduction in stroke risk and decreased need for anticoagulation. A surgical method of PLAATO implantation is proposed for its utility and efficacy in cardiac surgical procedures, where LAA occlusion is indicated as a primary procedure or as an adjunct. We describe a surgical method for PLAATO deployment in an experimental model that simulates various operative scenarios including right minithoracotomy, right video-assisted thoracoscopic, or median sternotomy.
Methods
The PLAATO LAA occlusion device was deployed into the LAA in six dogs using a right minithoracotomy incision and catheter deployment via direct left atrial access. Intracardiac echocardiography and left atrial angiography were used to size, position, and verify proper deployment of the device.
Results
Successful PLAATO deployment was achieved in six of the six dogs. One dog required replacement of an undersized device. One dog required replacement of an oversized device. Four dogs required minor repositioning for optimal positioning. Complete flush occlusion of the LAA was achieved in three dogs; the other three dogs had trace leak by LAA angiography.
Conclusions
Experimental surgical implantation of the PLAATO device produces stable and complete occlusion of the LAA. Potential surgical indications for PLAATO implantation include patients with AF where a percutaneous approach to LAA occlusion is contraindicated or in patients with AF who require concurrent cardiac surgery.
SingerD.E., AlbersG.W., DalenJ.E.Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest.2008; 133(suppl 6): 546S–592S.
2.
Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation.Analysis of pooled data from five randomized controlled trials. Arch Intern Med.1994; 154: 1449–1457.
3.
HartR.G., BenaventeO., McBrideR., PearceL.A.Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med.1999; 131: 492–501.
4.
HartR.G., PearceL.A., AguilarM.I.Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med.2007; 146: 857–867.
5.
Lloyd-JonesD., AdamsR., CarnethonM.Heart disease and stroke statistics—2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation.2009; 119: 480–486.
6.
FusterV., RydenL.E., CannomD.S.ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation.2006; 114: e257–e354.
7.
WannL.S., CurtisA.B., JanuaryC.T.2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Heart Rhythm.2011; 8: 157–176.
8.
LipG.Y., HartR.G., ConwayD.S.Antithrombotic therapy for atrial fibrillation. BMJ.2002; 325: 1022–1025.
9.
WaldoA.L., BeckerR.C., TapsonV.F.Hospitalized patients with atrial fibrillation and a high risk of stroke are not being provided with adequate anticoagulation. J Am Coll Cardiol.2005; 46: 1729–1736.
10.
StaffordR.S., SingerD.E.Recent national patterns of warfarin use in atrial fibrillation. Circulation.1998; 13: 1231–1233.
11.
LevineM.N., RaskobG., BeythR.J.Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest.2004; 126(suppl 3): 287S–310S.
12.
SchulmanS., BeythR.J., KearonC.Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest.2008; 133(suppl 6): 257S–298S.
13.
NagarakantiR., EzekowitzM.D., OldgrenJ.Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation.2011; 123: 131–136.
14.
ManningW.J., SilvermanD.I., KatzS.E.Impaired left atrial mechanical function after cardioversion: relation to the duration of atrial fibrillation. J Am Coll Cardiol.1994; 23: 1535–1540.
15.
Transesophageal echocardiographic correlates of thromboembolism in high-risk patients with nonvalvular atrial fibrillation.The Stroke Prevention in Atrial Fibrillation Investigators Committee on Echocardiography. Ann Intern Med.1998; 128: 639–647.
16.
Al-SaadyN.M., ObelO.A., CammA.J.Left atrial appendage: structure, function, and role in thromboembolism. Heart.1999; 82: 547–554.
17.
BlackshearJ.L., OdellJ.A.Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. Ann Thorac Surg.1996; 61: 755–759.
18.
ShiraniJ., AlaeddiniJ.Structural remodeling of the left atrial appendage in patients with chronic non-valvular atrial fibrillation: implications for thrombus formation, systemic embolism, and assessment by transesophageal echocardiography. Cardiovasc Pathol.2000; 9: 95–101.
19.
BlackshearJ.L., JohnsonW.D., OdellJ.A.Thoracoscopic extracardiac obliteration of the left atrial appendage for stroke risk reduction in atrial fibrillation. J Am Coll Cardiol.2003; 42: 1249–1252.
20.
DawsonA.G., AsopaS., DunningJ.Should patients undergoing cardiac surgery with atrial fibrillation have left atrial appendage exclusion?Interact Cardiovasc Thorac Surg.2010; 10: 306–311.
21.
HealeyJ.S., CrystalE., LamyA.Left Atrial Appendage Occlusion Study (LAAOS): results of a randomized controlled pilot study of left atrial appendage occlusion during coronary bypass surgery in patients at risk for stroke. Am Heart J.2005; 150: 288–293.
22.
JohnsonW.D., GanjooA.K., StoneC.D.The left atrial appendage: our most lethal human attachment! Surgical implications. Eur J Cardiothorac Surg.2000; 17: 718–722.
23.
KatzE.S., TsiamtsiourisT., ApplebaumR.M.Surgical left atrial appendage ligation is frequently incomplete: a transesophageal echocardiographic study. J Am Coll Cardiol.2000; 36: 468–471.
24.
MaddenJ.L.Resection of the left auricular appendix; a prophylaxis for recurrent arterial emboli. JAMA.1949; 140: 769–772.
25.
OdellJ.A., BlackshearJ.L., DaviesE.Thoracoscopic obliteration of the left atrial appendage: potential for stroke reduction?Ann Thorac Surg.1996; 61: 565–569.
26.
Cruz-GonzalezI., CubedduR.J., Sanchez-LedesmaM.Left atrial appendage exclusion using an Amplatzer device. Int J Cardiol.2009; 134: e1–e3.
27.
HolmesD.R., ReddyV.Y., TuriZ.G.Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet.2009; 374: 534–542.
28.
NakaiT., LeshM.D., GerstenfeldE.P.Percutaneous left atrial appendage occlusion (PLAATO) for preventing cardioembolism: first experience in canine model. Circulation.2002; 105: 2217–2222.
29.
BlockP.C., BursteinS., CasaleP.N.Percutaneous left atrial appendage occlusion for patients in atrial fibrillation suboptimal for warfarin therapy: 5-year results of the PLAATO (Percutaneous Left Atrial Appendage Transcatheter Occlusion) Study. JACC Cardiovasc Interv.2009; 2: 594–600.
30.
OstermayerS.H., ReismanM., KramerP.H.Percutaneous left atrial appendage transcatheter occlusion (PLAATO system) to prevent stroke in high-risk patients with non-rheumatic atrial fibrillation: results from the international multi-center feasibility trials. J Am Coll Cardiol.2005; 46: 9–14.
31.
SievertH., LeshM.D., TrepelsT.Percutaneous left atrial appendage transcatheter occlusion to prevent stroke in high-risk patients with atrial fibrillation: early clinical experience. Circulation.2002; 105: 1887–1889.
32.
CoxJ.L., AdN., PalazzoT.Current status of the Maze procedure for the treatment of atrial fibrillation. Semin Thorac Cardiovasc Surg.2000; 12: 15–19.
33.
BlockP.C.Percutaneous left atrial appendage closure in a patient with atrial fibrillation. Nat Clin Pract Cardiovasc Med.2006; 3: 456–460.
Garcia-FernandezM.A., Perez-DavidE., QuilesJ.Role of left atrial appendage obliteration in stroke reduction in patients with mitral valve prosthesis: a transesophageal echocardiographic study. J Am Coll Cardiol.2003; 42: 1253–1258.
36.
RosenzweigB.P., KatzE., KortS.Thromboembolus from a ligated left atrial appendage. J Am Soc Echocardiogr.2001; 14: 396–398.
37.
KanderianA.S., GillinovA.M., PetterssonG.B.Success of surgical left atrial appendage closure: assessment by transesophageal echocardiography. J Am Coll Cardiol.2008; 52: 924–929.
EdgertonJ.R., BrinkmanW.T., WeaverT.Pulmonary vein isolation and autonomic denervation for the management of paroxysmal atrial fibrillation by a minimally invasive surgical approach. J Thorac Cardiovasc Surg.2010; 140: 823–828.
40.
PrasadS.M., ManiarH.S., CamilloC.J.The Cox-maze III procedure for atrial fibrillation: long-term efficacy in patients undergoing lone versus concomitant procedures. J Thorac Cardiovasc Surg.2003; 126: 1822–1828.
41.
SchwartzmanD., KatzW.E., SmithA.J.Malpositioning of a left atrial appendage occlusion device? A case with implications for percutaneous transcatheter left atrial appendage occlusion device therapy. Heart Rhythm.2007; 4: 648–650.
